A bázisinzulin-analóg detemir helye a diabetológiai gyakorlatban: Bizonyítékok és lehetoségek

Translated title of the contribution: The long acting insulin analogue detemir in the diabetological practice: Evidence and potentials

Research output: Contribution to journalArticle

Abstract

Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.

Original languageHungarian
Pages (from-to)319-324
Number of pages6
JournalLege Artis Medicinae
Volume16
Issue number4
Publication statusPublished - Apr 2006

Fingerprint

Long-Acting Insulin
Insulin
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Albumins
Fatty Acids
Insulin Aspart
Isophane Insulin
Hypoglycemic Agents
Meals
Blood Glucose
Fasting
Carbon
Clinical Trials
Amino Acids
Weights and Measures
Insulin Detemir

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A bázisinzulin-analóg detemir helye a diabetológiai gyakorlatban : Bizonyítékok és lehetoségek. / Tamás, G.; Kerényi, Z.

In: Lege Artis Medicinae, Vol. 16, No. 4, 04.2006, p. 319-324.

Research output: Contribution to journalArticle

@article{82c2d73d7e1841e484b1125e10b85b50,
title = "A b{\'a}zisinzulin-anal{\'o}g detemir helye a diabetol{\'o}giai gyakorlatban: Bizony{\'i}t{\'e}kok {\'e}s lehetos{\'e}gek",
abstract = "Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.",
keywords = "Basal insulin, Insulin analogue, Insulin detemir, Insulin treatment",
author = "G. Tam{\'a}s and Z. Ker{\'e}nyi",
year = "2006",
month = "4",
language = "Hungarian",
volume = "16",
pages = "319--324",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "4",

}

TY - JOUR

T1 - A bázisinzulin-analóg detemir helye a diabetológiai gyakorlatban

T2 - Bizonyítékok és lehetoségek

AU - Tamás, G.

AU - Kerényi, Z.

PY - 2006/4

Y1 - 2006/4

N2 - Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.

AB - Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.

KW - Basal insulin

KW - Insulin analogue

KW - Insulin detemir

KW - Insulin treatment

UR - http://www.scopus.com/inward/record.url?scp=33746722102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746722102&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746722102

VL - 16

SP - 319

EP - 324

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 4

ER -